#HepatitisD
LightNews LightNews
noticiasdealmeria.bsky.social
Torrecárdenas estudia a 74 pacientes por hepatitis D en Almería:  Leer #hepatitisD #salud #diagnóstico
Torrecárdenas estudia a 74 pacientes por hepatitis D en Almería
 Leer
dlvr.it
October 13, 2026 at 3:28 PM
pharmaphorum.bsky.social
#Gilead's Hepcludex was the first drug to be cleared in the US for #hepatitisD in May, but a potential rival from #MirumPharma is already looming.

pharmaphorum.com/news/mirum-p...
Mirum puts Hepcludex in its sights with hep D readout
Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.
pharmaphorum.com
September 29, 2026 at 12:46 PM
ihieurope.bsky.social
🏥 Our @viromarkers.bsky.social project is shedding new light on the role of viral proteins in untreated chronic #HepatitisD in a bid to advance the development of new, effective treatments.

👉 link.europa.eu/WR3dC3
#HorizonEU
The text reads: Project news Illuminating the role of viral proteins in untreated chronic hepatitis D The image shows a doctor pointing at a model of a liver standing on a desk. Other visuals are the IHI logo and the logos of our partners.
September 17, 2026 at 10:28 AM
isbt.bsky.social
Findings underscore the importance of continued HBV prevention, including vaccination, to protect blood donors and the wider community.

onlinelibrary.wiley.com/doi/abs/10.1...

#BloodSafety #HepatitisD #HBV #GlobalHealth #Research #Cameroon
Seroprevalence of hepatitis D virus among blood donors with hepatitis B surface antigen at Yaounde Central Hospital, Cameroon
Background and Objectives Hepatitis delta virus (HDV) superinfection with hepatitis B virus (HBV) infection can cause a severe form of viral hepatitis. A nation-wide general population study in Came...
onlinelibrary.wiley.com
March 31, 2026 at 8:07 AM
aasldnews.bsky.social
This #HepatitisAwarenessMonth, AASLD member Chari Cohen, President of Hepatitis B Foundation, reflects on the new advances in #hepatitisB and #hepatitisD diagnostics and treatment are creating new momentum in the fight against #viralhepatitis.
May 13, 2026 at 2:00 PM
ihieurope.bsky.social
🌍 On #WorldHepatitisDay, discover how our @viromarkers.bsky.social project is advancing markers to predict which patients will respond best to new #HepatitisD drug #bulevirtide.
👉 europa.eu/!FfGjJN
#hepatitis #IHITransformingHealth #HorizonEU
VIROMARKERS aims for revolution in care of people with persistent viral infections
The new project is advancing biomarkers that would improve the care of people living with HIV and hepatitis D, plus stem cell transplant patients at risk of cytomegalovirus (CMV).
europa.eu
July 28, 2025 at 9:37 AM
europeliver.bsky.social
Let’s Talk Hepatitis D!
Many people living with Hepatitis D (HDV) remain undiagnosed—but early detection can change lives. 💪

🩺 Screening. Diagnosis. Therapy.
Early diagnosis is the key to managing HDV

#HepatitisD #LiverHealth #ScreenForLife #HepBShot #HepatitisAwareness #LinkToCare #WorldHepatitis
July 21, 2025 at 4:49 AM
reibergerthomas.bsky.social
Treatment response to #Bulevirtide is linked to amelioration of #PortalHypertension in patients with chronic #HepatitisD

JHEP Reports
www.jhep-reports.eu/article/S258...
December 5, 2025 at 4:59 AM
gtt-vih.bsky.social
La aprobación de bulevirtida abre una nueva etapa en el abordaje de la hepatitis D.

📲 Lee «La Noticia del Día» de gTt-VIH 🧡

🔗 www.gtt-vih.org/publicacione...

#HepatitisD
June 4, 2026 at 12:03 PM
4040rec.bsky.social
#Bluejay #BluejayTherapeutics #phase3trial #brelovitug #BJT778 #hepatitisD #AZURE2study #CHD #hepatitisDvirus #cirrhosis #livercancer #viralhepatitis #liverdisease #BreakthroughTherapydesignation #FDA #PRIMEdesignation #Orphanstatus #OrphanDrug #EMA
pharmatimes.com/news/bluejay...
Bluejay begins phase 3 trial of brelovitug for hepatitis D - PharmaTimes
First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex
pharmatimes.com
September 10, 2025 at 12:03 PM
gesvirologie.bsky.social
Anlässlich der diese Woche erfolgten Zulassung durch die US-amerikanische Gesundheitsbehörde FDA nocheinmal unser Post vom vergangenen Jahr mit Link auf eine TWiV Episode mit dem „Erfinder“ dieses #HepatitisD -Medikaments, Prof. Stephan Urban @ciid-heidelberg.bsky.social und @dzif.bsky.social! (MB)
gesvirologie.bsky.social GfV - Gesellschaft für Virologie @gesvirologie.bsky.social · Apr 22
One of the big success stories in current German virology: the discovery of a small peptide in the #Hepatitis B virus #HBV, and its development towards a clinical #HDV (and HBV!) entry inhibitor by Stephan Urban @ciid-heidelberg.bsky.social @uniheidelberg.bsky.social
(MB)

youtu.be/JcdtRNaTHpM?...
TWiV Special: A shot of HepB with Stephan Urban
YouTube video by MicrobeTV
youtu.be
May 29, 2026 at 7:12 AM
pharmaphorum.bsky.social
#HuahuiHealth has won the #firstapproval in #China for a drug to treat chronic infections with #hepatitisD virus (HDV), plugging a major gap in treatment options.
China clears its first drug for chronic hepatitis D
Huahui Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus.
buff.ly
January 27, 2026 at 5:30 PM
contagionlive.bsky.social
nChroma Bio raises $75M to advance CRMA-1001, a liver-targeted epigenetic therapy for chronic hepatitis B and D, with clinical trials set for 2025. #HepatitisB #HepatitisD #MEDsky #IDsky
Read more: www.contagionlive.com/view/nchroma...
nChroma Bio Raises $75M to Advance Epigenetic Editing for Hepatitis B and D Cure
The development of CRMA-1001, a potential functional cure for chronic hepatitis B and D, is set to enter clinical trials in 2025.
www.contagionlive.com
December 13, 2024 at 6:57 PM
thebinderlab.bsky.social
Infos zu #HepatitisD (#HDV) und dem Medikament: https://www.klinikum.uni-heidelberg.de/newsroom/eine-chronische-krankheit-wird-therapierbar/

Artikel zum Gilead-Kauf:...
February 2, 2025 at 1:41 AM
gastroagi.bsky.social
AASLD 2025 SOLSTICE Ph2: Tobevibart ± elebsiran in chronic #HepatitisD. Wk48 undetectable HDV RNA: 66% combo vs 48% mono; HBsAg <10 IU/mL: 91% vs 21%. Safe, well tolerated, no ALT flares. Promising dual HBV/HDV targeting.

🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 7:05 AM
thervacb-eu.bsky.social
Let's break down #hepatitisD therapies for #WHD2026💚
👩‍⚕️D-SOLVE #hepatologist Elisabetta Degasperi explains today's HBV treatment landscape - from current care and bulevirtide to promising therapies in development - for people living with #HBV and #HDV.
📺 tinyurl.com/HDVtherapies
#TherVacB #LiverSky
Which new treatment options are available for hepatitis D?
YouTube video by TherVacB - Awareness & Insights on Hepatitis B
youtu.be
July 28, 2026 at 12:45 PM
thervacb-eu.bsky.social
💡 Sie suchen fundierte Informationen zu #HepatitisB & #HepatitisD?
Die Kampagne „Aufklärung zu #HDV & #HBV“ von #TherVacB & #DSOLVE erklärt Co-Infektion, Diagnose und Therapie in Videos mit Expertinnen & Patientenperspektiven⚕️

📺 Zur Videoreihe: tinyurl.com/HepatitisBDW...

#WHT2025 #HepSky
TherVacB & D-Solve unterstützen den Welt-Hepatitis-Tag 2025 mit ihrer Kampagne „Aufklärung über HDV und HBV“
Gut informiert, besser geschützt mit unserer Kampagne „Aufklärung über HDV und HBV“ - alles, was Sie über Hepatitis D und B wissen sollten
tinyurl.com
July 25, 2025 at 1:22 PM
thervacb-eu.bsky.social
💡 Looking for trusted info on #HepatitisB & #HepatitisD?

The #TherVacB & #DSOLVE video campaign “Insights on #HDV & #HBV” explains co-infection, diagnosis & treatment in expert-led, patient-focused videos⚕️

📺 Explore the full resource: tinyurl.com/HepatitisBDInsights

#WHD2025 #LiverSky
World Hepatitis Day 2025 with Ongoing Awareness Campaign “Insights on HDV and HBV”
Stay informed, stay protected with our campaign “Insights on HDV and HBV” – everything you need to know about hepatitis D and B.
tinyurl.com
July 25, 2025 at 10:23 AM
agentictribune.bsky.social
FDA Approves Hepcludex, First U.S. Treatment for Chronic Hepatitis Delta

#hepatitisd #fda #gilead #antivirals
FDA Approves Hepcludex, First U.S. Treatment for Chronic Hepatitis Delta
The FDA cleared Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis D, the first approved U.S. therapy for this serious liver infection.
agentictribune.com
May 22, 2026 at 5:38 PM
dzif.bsky.social
#Hepcludex (bulevirtide) is now approved for the treatment of chronic hepatitis D infection by the U.S. Food and Drug Administration (FDA). With FDA approval, the hepatitis drug is now available in the most significant global pharmaceutical market. #HDV #HepatitisD

➡️ t1p.de/hepcludex-fda
May 27, 2026 at 12:05 PM
melodieweller.bsky.social
Anyone seeing reports of patients with #HepatitisD in the absence of #HepatitisB? My team is detecting #HDV antigens and RNA in salivary glands of #Sjogrens patients without evidence of #HBV. Thinking its more widespread. Current testing guidelines would miss. #ViroSky #LiverSky #GastroSky
April 4, 2025 at 11:13 AM
melodieweller.bsky.social
New #Feed: #HDV #HepD #HepatitisD #HepatitisDVirus #HDV-like #Kolmioviridae #HepDVirus Tracking the latest in HDV and HDV-like viruses, from new publications to scientific breakthroughs and global events. Exploring virology, epidemiology, treatments, and diagnostics.

bsky.app/profile/did:...
March 2, 2025 at 12:07 PM
d-solve-consortium.bsky.social
🎥 New video in our #HDVAwareness series! Dott.ssa Elisabetta Degasperi (#D-SOLVE) presents novel therapy options for #HepatitisD and what they mean for patients. #Hepatitis #HaDEA #EUHealth #LiverHealth@ec.europa.eu ▶️ youtu.be/6MfgaO6frn0?...
Which new treatment options are available for hepatitis D?
YouTube video by TherVacB - Awareness & Insights on Hepatitis B
youtu.be
July 28, 2026 at 8:15 AM
d-solve-consortium.bsky.social
🎙️ Live now! Prof. Eui-Cheol Shin (KAIST, Korea) is presenting “Cytokine-induced bystander CD8+ T cell activation and its regulation in viral hepatitis” – part of our Translational Seminar Series.
Join the discussion live 👉 msteams.link/DGTP
#HepatitisD #D-SOLVE #HaDEA #EUHealth
December 8, 2025 at 4:07 PM
d-solve-consortium.bsky.social
🧬 D-SOLVE lecture via MS Teams:
Hepatitis D in Mongolia – Screening Study among Mongol Migrants in Sweden
👤 Speakers from Karolinska/Sweden & Mongolia
🗓️ Tue, 23 Sept | 🕐 12:45–13:30 CET
🔗 bit.ly/46oxjnH
🔑 ID: 368 532 223 585 | PW: dq64Nb9t
#DSOLVE #HepatitisD #PublicHealth
September 17, 2025 at 11:04 AM